Publications by authors named "Cheng Shang See"

Claim this Profile
P
Prodrugs of the cancer cell selective anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131) are orally efficacious in a mouse model of resistant colon cancer.
Cheng Shang See, Mayumi Kitagawa, Pei-Ju Liao, Kyung Hee Lee, Jasmine Wong

Bioorg Med Chem Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131).
Cheng Shang See, Mayumi Kitagawa, Pei-Ju Liao, Kyung Hee Lee, Jasmine Wong

Eur J Med Chem· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Brian W Dymock, Cheng Shang See

Expert Opin Ther Pat· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing mobile networks for the detection of clinically relevant interactions between chemotherapy regimens and complementary and alternative medicines.
Kevin Yi-Lwern Yap, Cheng Shang See, En Yi Kuo, Wai Keung Chui, Alexandre Chan

J Altern Complement Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer.
Kevin Yi-Lwern Yap, Cheng Shang See, Alexandre Chan

Recent Pat Food Nutr Agric· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis